Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.

Articles Authored by Andrew P. Han
SomaLogic CEO Steps Down Amid Board Turnover; Firm's Q4 Revenues Drop 18 Percent
Ex-CEO Roy Smythe is one of three people stepping down from the board. He will be replaced by Adam Taich, formerly executive VP of life sciences at SomaLogic.
Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.
Layoffs at Life Science, Dx Firms Continue as Thermo Fisher Scientific, Natera Shrink Payrolls
In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.
SomaLogic Seeks 'Strategic Alternatives' for Dx Business to Focus on Life Science Market
The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts.
Evolving Akoya Biosciences Touts CDx Partnerships at JP Morgan Conference
The Marlborough, Massachusetts-based firm also announced new panels for its PhenoCycler-Fusion and PhenoImager HT spatial analysis platforms.
Natera Eyes Regulatory Path for Signatera as Companion Diagnostic
The firm isn't planning a strategy for a kitted version of the test, though company officials said they were open to that in the future.
Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay
Premium
The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.
AMP, CAP Release Guidelines for Use of In Silico Approaches for Validating NGS Data Pipelines
Labs should not let in silico data supplant physical specimens in bioinformatic validation and should understand the limitations of such data.
EU to Disallow Illumina's Grail Purchase
Separately, the US Federal Trade Commission said it will appeal an administrative law judge's initial decision in an antitrust case that was favorable to Illumina.
Illumina Says Judge Issued Favorable Decision in FTC Challenge to Grail Acquisition
According to the firm, the judge "rejected the FTC's position that the deal would adversely affect competition" of multi-cancer early detection tests.